Lineage Cell Therapeutics (LCTX) Q4 2024 Annual Earnings
LCTX·Reported March 10, 2025·After market close
Lineage Cell Therapeutics reported Q4 2024 revenue of $2.9M, beat analyst consensus of $1.4M by $1.5M. Diluted EPS came in at $-0.01, beat the $-0.04 consensus by $0.03.
Revenue
$2.9Mbeat by $1.5M
Consensus: $1.4MDiluted EPS
$-0.01beat by $0.03
Consensus: $-0.04
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Lineage Cell Therapeutics's Q4 2024 earnings report.
Lineage Cell Therapeutics (LCTX) reported Q4 2024 earnings on March 10, 2025 after market close.
Lineage Cell Therapeutics reported revenue of $2.9M and diluted EPS of $-0.01 for Q4 2024.
Revenue beat the consensus estimate of $1.4M by $1.5M. EPS beat the consensus estimate of $-0.04 by $0.03.
You can read the 10-K periodic report (0000950170-25-036309) directly on SEC EDGAR. The filing index links above go to sec.gov.